2008
p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis*
Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM. p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis*. Journal Of Biological Chemistry 2008, 283: 14132-14143. PMID: 18347024, PMCID: PMC2376243, DOI: 10.1074/jbc.m708034200.Peer-Reviewed Original ResearchConceptsCultured hippocampal neuronsAlzheimer's diseaseHippocampal neuronsDendritic spinesTransgenic miceAlzheimer's disease brainAlzheimer's amyloid pathologyAlzheimer's disease (AD) pathogenesisBeta-amyloid oligomersOligomer treatmentSrc family tyrosine kinase inhibitor PP2P-NR2BSynaptic deficitsAmyloid pathologyDisease brainTyrosine kinase inhibitor PP2Disease pathogenesisCognitive deficitsMental retardation syndromeProtein drebrinKinase inhibitor PP2DiseaseNeuronsRetardation syndromeMice
2007
Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo
Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo. Cancer Research 2007, 67: 1769-1774. PMID: 17308119, DOI: 10.1158/0008-5472.can-06-3783.Peer-Reviewed Original ResearchConceptsLiver metastasesMetastasis ScoreBALB/c miceCancer metastasisCancer cellsMediator of intracellularColon cancer metastasisProtein therapySplenic injectionClinical efficacyControl miceDelivery of p53Significant clinical potentialC micePortal veinColon cancer cellsImmunohistochemical stainingMouse modelSecond injectionMetastasisClinical potentialMiceTherapyVivoP53